Provided by Tiger Trade Technology Pte. Ltd.

Aprea Therapeutics, Inc.

0.6094
+0.01672.82%
Post-market: 0.5804-0.0290-4.76%19:58 EST
Volume:184.64K
Turnover:108.46K
Market Cap:4.26M
PE:-0.29
High:0.6439
Open:0.5868
Low:0.5610
Close:0.5927
52wk High:3.72
52wk Low:0.5480
Shares:6.99M
Float Shares:4.56M
Volume Ratio:0.77
T/O Rate:4.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1364
EPS(LYR):-2.3519
ROE:-74.72%
ROA:-41.90%
PB:0.39
PE(LYR):-0.26

Loading ...

BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics

Reuters
·
Feb 12

Aprea Therapeutics Inc - Existing Issued Patents Expected to Remain in Force Through 2035-2037

THOMSON REUTERS
·
Feb 12

Aprea Therapeutics Inc - Granted New Patents in Australia and Japan

THOMSON REUTERS
·
Feb 12

Aprea Therapeutics Inc - Core Patent Families Expected to Provide Exclusivity Into 2045

THOMSON REUTERS
·
Feb 12

Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio

Reuters
·
Feb 12

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (Ddr) Cancer Therapeutics, Paving Way for Pipeline Growth

THOMSON REUTERS
·
Feb 12

Aprea Therapeutics Names Eugene Kennedy as Chief Medical Advisor

Reuters
·
Feb 04

Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares

Reuters
·
Feb 03

Aprea Therapeutics CFO John P. Hamill Acquires Common Shares

Reuters
·
Feb 03

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:52 AM

Reuters
·
Jan 31

Aprea Therapeutics prices 6.29M shares at 89c in private placement

TIPRANKS
·
Jan 29

Aprea Therapeutics announces early PoC data in ACESOT-1051 trial

TIPRANKS
·
Jan 29

Aprea Therapeutics Reports Early Proof-of-Concept for WEE1 Inhibitor APR-1051 in Solid Tumors

Reuters
·
Jan 29

Aprea Therapeutics Inc - 50% Reduction in Lesion, 90% Decrease in CA-125 in Patient

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Announces Early Clinical Proof-of-Concept in the Ongoing Acesot-1051 Dose-Escalation Trial Evaluating Wee1 Inhibitor Apr-1051, Including Partial Response Observed on First Scan

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Inc - Unconfirmed Partial Response at 150 Mg Dose

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Inc: Additional Updates in First Half of 2026 and Completing Dose Escalation Later in Year

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Announces $5.6 Million Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price

Reuters
·
Jan 26

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Reuters
·
Dec 22, 2025